Physician profile
Timothy Maynard
NPI 1942618657
$8,147.08
in general payments reported to CMS, 2019-2025
42 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,689 · 2022: $1,628 · 2023: $1,412 · 2024: $1,563 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.18 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,264.04 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $892.98 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $476.40 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $460.06 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $386.40 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $273.20 | 2021-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $251.11 | 2022-2025 | Rexulti |
| Pfizer INC. | $225.49 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $213.84 | 2021-2024 | Fanapt |
| Idorsia Pharmaceuticals US INC | $204.59 | 2023 | Quviviq |
| Alkermes, INC. | $183.91 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $140.83 | 2023-2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $135.71 | 2021-2023 | Trulicity, Mounjaro, Jardiance |
| Jazz Pharmaceuticals INC. | $128.50 | 2021-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.